Ambrx Biopharma Inc.

Ambrx (Nasdaq: AMAM) is a clinical stage biopharmaceutical company that specializes in the discovery and development of next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. The company utilizes an expanded genetic code technology platform to advance a portfolio of clinical and preclinical programs focused on optimizing efficacy and safety in multiple cancer indications. Ambrx's proprietary antibody-drug conjugats (ADC) include Arx517 for targeting the prostate-specific membrane antigen (Psma) and Arx788 for targeting HER2. It was spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of its protein engineering technology.